NCT03403777View on ClinicalTrials.gov

Avelumab in Refractory Testicular Germ Cell Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Testicular NeoplasmsNeoplasms, Germ Cell and EmbryonalNeoplasmsTesticular DiseasesGonadal DisordersAntineoplastic AgentsMolecular Mechanisms of Pharmacological Action
Interventions
DRUG

Avelumab

AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.

Trial Locations (1)

83310

National Cancer Institute, Bratislava

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT03403777 - Avelumab in Refractory Testicular Germ Cell Cancer. | Biotech Hunter | Biotech Hunter